transcobalamin 2Genealiases: D22S676 · D22S750 · II · TC · TC II · TC-2
Q-omics provides the consensus-scored TCN2 profile across patient tissues and cancer cell-line models. TCN2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TCN2 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, TCN2 RNA expression shows 16,000 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where TCN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCN2 survival associations across molecular data types. TCN2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCN2 RNA expression–survival associations across cancer types. High TCN2 expression shows unfavorable associations in LIHC, KICH and STAD, but favorable associations in KIRC, CESC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TCN2 RNA expression.
This table summarizes TCN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TCN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCN2 shows lower tumor expression in KICH, COAD, BRCA, BLCA and LUSC and higher tumor expression in KIRC. The KICH box plot shows higher TCN2 RNA expression in normal versus tumor tissue (log2 FC = −3.099, t-test p < 0.001).
This table shows molecular features associated with TCN2 in patient tissues and cancer cell lines. In patient samples, TCN2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TCN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BREAST.
